Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.98 |
| ▸ | LCK | P06239 | 4/20 | 0.98 |
| ▸ | LYN | P07948 | 4/20 | 0.98 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.79 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.79 |
| ▸ | SRC | P12931 | 3/20 | 0.74 |
| ▸ | KDR | P35968 | 2/20 | 0.74 |
| ▸ | TEK | Q02763 | 1/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.70 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | TEC | P42680 | 4/20 | 0.67 |
| ▸ | BMX | P51813 | 4/20 | 0.67 |
| ▸ | ITK | Q08881 | 3/20 | 0.67 |
| ▸ | BLK | P51451 | 3/20 | 0.67 |
| ▸ | TXK | P42681 | 2/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586962 | 0.99 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL6431516 | 0.99 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| Pyrimidine SCHEMBL7047852 | 0.94 | BTK (0.90) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL25466299 | 0.90 | BTK (0.80) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL15915382 | 0.90 | BTK (0.84) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL2631407 | 0.90 | BTK (0.84) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL19335138 | 0.90 | BTK (0.79) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL19335172 | 0.90 | BTK (0.79) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22364036 | 0.90 | BTK (0.79) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL2360644 | 0.90 | BTK (0.79) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021195439-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2020263935-A1 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-15 | — | — | US | disclosed |
| US-9834561-B2 | Process for preparing ibrutinib and its intermediates | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-05 | — | — | US | disclosed |
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | SANDOZ AG (CH) | 2017-11-16 | — | — | US | disclosed |
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | SANDOZ AG (CH) | 2017-11-16 | — | — | US | disclosed |
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | SANDOZ AG (CH) | 2017-11-16 | — | — | US | disclosed |
| EP-3212624-A1 | SYNTHESIS OF SUBSTITUTED 1H-PYRAZOLO[3,4-D]PYRIMIDINES | Sandoz AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20170145017-A1 | PROCESS FOR PREPARING IBRUTINIB AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-05-25 | — | — | US | disclosed |
| WO-2016066673-A1 | SYNTHESIS OF SUBSTITUTED 1H-PYRAZOLO[3,4-D]PYRIMIDINES | SANDOZ AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066673-A1 | SYNTHESIS OF SUBSTITUTED 1H-PYRAZOLO[3,4-D]PYRIMIDINES | SANDOZ AG (CH) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | BTK, ABL1, SYK | BTK 1/4885LCK 10/4885LYN 6/4885 |
| US-20170145017-A1 | PROCESS FOR PREPARING IBRUTINIB AND ITS INTERMEDIATES | BTK, SYK, MYD88 | BTK 1/4885LCK 27/4885LYN 5/4885 |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | BTK 1/4885LCK 20/4885LYN 10/4885 |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | BTK, SYK, ABL1 | BTK 1/4885LCK 20/4885LYN 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.